Founded in 1997 and headquartered in Zhuhai, China, our company is dedicated to the development, manufacturing, and promotion of cost-effective, high-quality generic drugs and API. Our product line focuses on the fundamental therapeutic areas of Cardiovascular, Gastrointestinal, and CNS. We have been acknowledged for our compliance with cGMP and ICH guidelines by regulatory authorities such as NMPA, USFDA, PMDA, and MFDS (Korea). Zhuhai Rundu Pharmaceutical Co., Ltd. is a contemporary scientific and technological pharmaceutical enterprise that integrates drug research and development, production, and distribution. Situated in Jinwan District, Zhuhai City, Guangdong Province, it was established in 1999 and became publicly listed on the Shenzhen Stock Exchange on January 5, 2018 (stock abbreviation: Rundu; stock code: 002923). The company's primary operations revolve around the research and development, production, and sales of chemical-pharmaceutical preparations, chemical raw materials, and pharmaceutical intermediates.